Cargando…

Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19

With the outbreak and rapid spread of COVID-19, the world health situation is unprecedentedly severe. Systemic lupus erythematosus (SLE) is a common autoimmune disease, which can cause multiple organ damage. Numerous studies have shown that immune factors have important roles in the pathogenesis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Bangyi, Li, Siying, Ye, Jujian, Liu, Yi, Hu, Longtai, Tang, Yan, Wu, Zhijian, Zhang, Peidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527889/
https://www.ncbi.nlm.nih.gov/pubmed/34710657
http://dx.doi.org/10.1016/j.intimp.2021.108254
_version_ 1784586158456438784
author Zhou, Bangyi
Li, Siying
Ye, Jujian
Liu, Yi
Hu, Longtai
Tang, Yan
Wu, Zhijian
Zhang, Peidong
author_facet Zhou, Bangyi
Li, Siying
Ye, Jujian
Liu, Yi
Hu, Longtai
Tang, Yan
Wu, Zhijian
Zhang, Peidong
author_sort Zhou, Bangyi
collection PubMed
description With the outbreak and rapid spread of COVID-19, the world health situation is unprecedentedly severe. Systemic lupus erythematosus (SLE) is a common autoimmune disease, which can cause multiple organ damage. Numerous studies have shown that immune factors have important roles in the pathogenesis of both COVID-19 and SLE. In the early stages of COVID-19 and SLE pathogenesis, IFN-α expression is frequently increased, which aggravates the virus infection and promotes SLE development. In addition, increased IL-6 levels, caused by different mechanisms, are observed in the peripheral blood of patients with severe COVID-19 and SLE, stimulating a series of immune cascades that lead to a cytokine storm, as well as causing B cell hyperfunction and production of numerous of antibodies, aggravating both COVID-19 and SLE. In this review, we explore the background immunopathological mechanisms in COVID-19 and SLE and analyze the advantages and disadvantages of commonly used SLE drugs for patients with COVID-19, to optimize treatment plans for patients with SLE who develop COVID-19.
format Online
Article
Text
id pubmed-8527889
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-85278892021-10-21 Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 Zhou, Bangyi Li, Siying Ye, Jujian Liu, Yi Hu, Longtai Tang, Yan Wu, Zhijian Zhang, Peidong Int Immunopharmacol Article With the outbreak and rapid spread of COVID-19, the world health situation is unprecedentedly severe. Systemic lupus erythematosus (SLE) is a common autoimmune disease, which can cause multiple organ damage. Numerous studies have shown that immune factors have important roles in the pathogenesis of both COVID-19 and SLE. In the early stages of COVID-19 and SLE pathogenesis, IFN-α expression is frequently increased, which aggravates the virus infection and promotes SLE development. In addition, increased IL-6 levels, caused by different mechanisms, are observed in the peripheral blood of patients with severe COVID-19 and SLE, stimulating a series of immune cascades that lead to a cytokine storm, as well as causing B cell hyperfunction and production of numerous of antibodies, aggravating both COVID-19 and SLE. In this review, we explore the background immunopathological mechanisms in COVID-19 and SLE and analyze the advantages and disadvantages of commonly used SLE drugs for patients with COVID-19, to optimize treatment plans for patients with SLE who develop COVID-19. Published by Elsevier B.V. 2021-12 2021-10-14 /pmc/articles/PMC8527889/ /pubmed/34710657 http://dx.doi.org/10.1016/j.intimp.2021.108254 Text en © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zhou, Bangyi
Li, Siying
Ye, Jujian
Liu, Yi
Hu, Longtai
Tang, Yan
Wu, Zhijian
Zhang, Peidong
Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
title Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
title_full Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
title_fullStr Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
title_full_unstemmed Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
title_short Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
title_sort immunopathological events surrounding il-6 and ifn-α: a bridge for anti-lupus erythematosus drugs used to treat covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527889/
https://www.ncbi.nlm.nih.gov/pubmed/34710657
http://dx.doi.org/10.1016/j.intimp.2021.108254
work_keys_str_mv AT zhoubangyi immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT lisiying immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT yejujian immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT liuyi immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT hulongtai immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT tangyan immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT wuzhijian immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19
AT zhangpeidong immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19